AMG-794

N/A

Report date: 2026/03/19 17:18:28

Base Information

Drug NameAMG-794

Drug Alias NameAMG-794

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CLDN6Anti-CD3

TargetsClaudin 6T cell surface glycoprotein CD3

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Ovarian Epithelial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSwitzerland

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmgen Inc

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, Ovarian Epithelial

Other Information

ATC CodeN/A